66 results about "Spectrum disorder" patented technology

Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.

The application relates to the technical field of image recognition, in particular to a children autism spectrum disorder stereotyped behavior recognition system based on video images. The system screens target pixel points from pixel points; determines a motion intensity index according to a trajectory point sequence of the target pixel points; converts the trajectory point sequence of the target pixel points into a motion vector sequence; determines direction similarity according to direction similarity between vectors; clusters the vectors based on the direction similarity, and identifies a target cluster; determines a motion regularity index according to the number of vectors in the target cluster and the direction similarity; determines a saliency index in combination with the motion intensity index; clusters the target pixel points based on the saliency index, and sets a region of interest; determines an enhancement weight according to the density of the target pixel points in the region and the saliency index; and determines a total enhancement demand value in combination with the gray scale and gradient features of the pixel points in the region; and reversely maps the total enhancement demand value into a gamma correction parameter, so that the accuracy of recognition is improved.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

This invention relates to the field of pharmaceutical technology, and discovers that the natural products boldinine and norboldinine can be used as NTSR1 (Neurotensin receptor-1, NTSR1) receptor antagonists and their applications. The compounds are boldinine and norboldinine ((+)-Laurolitsine), which have NTSR1 receptor antagonistic activity and are NTSR1 receptor antagonists that can prevent and treat alcohol poisoning, addiction, schizophrenia, autism spectrum disorder, and mood disorders. Accordingly, this invention can provide novel NTSR1 receptor antagonist prospective compounds with clear targets for the above-mentioned related diseases.

A method for early diagnosis of autism spectrum disorder (ASD) including determining an ASD risk index, determining an ASD brain index that includes administering at least one auditory brainstem response (ABR) test to an ear canal of a patient, producing a plurality of biomarkers and identifying at least one biomarker of the plurality of biomarkers as a potential ASD biomarker, and determining an ASD likelihood responsive to each of the ASD risk index and ASD brain index.

Embodiments of the instant disclosure relate to intervention and / or treatment of autism spectrum disorder (ASD). Certain embodiments relate to treating a subject having ASD with one or more proinflammatory cytokines. In some embodiments, the one or more proinflammatory cytokines include, but are not limited to, granulocyte-macrophage colony-stimulating factor (GM-CSF) or derivative thereof, or fusion polypeptide thereof, or recombinant thereof. Other embodiments include a mouse model for assessing efficacy of treatment of ASD in humans and other mammals.

Provided is an AAV vector capable of expressing a human Mef2c gene in the brain. Specifically, provided are an adeno-associated virus vector capable of expressing a full-length MEF2C protein, and the use thereof. The adeno-associated virus vector can significantly ameliorate the social deficit symptoms of mice with Mef2c gene deletion.

To provide a more effective medicine for treating ASD.SOLUTION: A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 1a receptor antagonist. A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 30IU receptor antagonist. A therapeutic agent for autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 1a receptor; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the pharmaceutical composition comprises an oxytocin-receptor agonist and a vasopressin 1a receptor antagonist as active ingredients; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 30IU receptor; and a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the vasopressin-receptor antagonist is SR49059. 1a.SELECTED DRAWING: None

In some embodiments, a composition comprising Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus plantarum, and Streptococcus thermophilus is provided. In some embodiments, provided is the use of a composition of any of the examples herein for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorder (ASD), anxiety disorder and / or gastrointestinal (GI) disorder or condition, enhancing attention and / or concentration, or stimulating a GABA receptor in a subject. In some embodiments, methods and kits are provided for preventing or alleviating anxiety and / or sensory hypersensitivity, preventing or treating autism spectrum disorders, anxiety disorders, and / or gastrointestinal disorders or conditions, enhancing attention and / or concentration, or stimulating GABA receptors in a subject. In certain embodiments, the compositions are safe to use and effective to prevent or alleviate anxiety and / or sensory hypersensitivity in subjects, particularly children subjects.

Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.

The present invention relates to a system for early screening of autism spectrum disorder using eye tracking. According to the present invention, autism spectrum disorder may be diagnosed early by applying response data of a user's gaze, which reacts to images or videos outputted on a display, to an autism spectrum disorder screening model. In addition, the present invention may be used to easily check a degree of suspicion of autism spectrum disorder at home, and thus may be utilized in the fields of early diagnosis, prevention, and treatment of autism in children.

This invention relates to the field of biomedical technology, specifically disclosing the application of betaine in the preparation of drugs for treating autism. Through experiments using a valproic acid-induced mouse model of autism spectrum disorder, this invention found that betaine can significantly improve social impairments and repetitive, stereotyped behaviors in the model mice, and exhibits stable and reproducible effects in both 1-month-old and 2-month-old male offspring. This invention reveals a novel use of betaine in treating core behavioral deficits in autism spectrum disorder (ASD), providing a new source of natural active ingredients for the preparation of drugs for treating autism.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The embodiment of the application provides a kind of child behavior abnormality evaluation method and system, in the case where the child to be measured is located at least one test scene shown in test room, the behavior test data of the child to be measured collected by the data acquisition equipment arranged in test room is acquired;The behavior test data of the child to be measured is analyzed and processed, and the behavior characteristics of the child to be measured are determined;According to behavior characteristics, the probability that the child to be measured exists behavior abnormality is evaluated.The test scene corresponds to the abnormal behavior type to be evaluated of the child to be measured, and the abnormal behavior type includes at least one performance behavior corresponding to autism spectrum disorder.That is, the behavior test data of the child to be measured in real scene is collected by data acquisition equipment, to record the real action and behavior of the child to be measured comprehensively and accurately.In this way, the possibility of abnormal behavior of the child to be measured can be evaluated by analyzing behavior test data, which shortens the test time and improves the evaluation efficiency of abnormal behavior.

The application discloses a primer group, a kit and application for screening autism spectrum disorder patients, and belongs to the field of disease diagnosis. The technical problem solved by the application is how to screen autism spectrum disorder patients in Chinese Han population. The primer group for screening autism spectrum disorder patients disclosed by the application is directed to 132 autism susceptible gene sites, and is composed of 264 single-stranded DNAs shown in SEQ ID No. 1 to SEQ ID No. 264. According to the 132 autism susceptible gene sites, a data model is established by SVM, autism spectrum disorder patients can be screened, and the data model has good accuracy, precision, recall rate, F1 score and AUC value, can provide stable and efficient prediction performance between balanced precision and recall rate, and has strong ability in distinguishing autism spectrum disorder patients and healthy individuals.

The invention relates to the technical field of neural image analysis, and particularly provides a brain function connection intelligent screening method and system for autism spectrum disorders, and the method comprises the steps: firstly obtaining resting state functional magnetic resonance imaging data and phenotype information thereof, and extracting a blood oxygen level dependence value time sequence of each brain region after preprocessing; then constructing a multi-scale brain network comprising a low-order function connection matrix and at least one high-order function connection matrix; the matrix is converted into a brain function connection graph containing sub-graphs of different scales through threshold sparsification; meanwhile, phenotype embedding features are extracted from phenotype information; the graph data and the phenotypic features are input into a multi-channel neural network model for parallel processing and fusion, and joint feature representation is obtained; and finally, outputting an auxiliary diagnosis result of the autism spectrum disorder through the classifier. According to the method, by fusing the multi-scale brain function connection information and the individual phenotype features, the accuracy of autism classification diagnosis and the generalization ability of the model are effectively improved.

In one embodiment of the present invention, the present invention relates to a pharmaceutical composition for treating an individual having a disorder selected from communication disorders, motor impairments, cognitive impairments, mental disorders, sensory disorders, autism spectrum disorders, and pervasive developmental disorders, the pharmaceutical composition comprising L-serine or a pharmaceutically acceptable salt thereof.

The present application relates to the technical field of medicine. Disclosed for the first time is a chemogenetic gene therapy technology for treating autism spectrum disorder. Specifically, provided in the present technology is a combined drug treatment strategy, which comprises a neuron-targeted intracranial injection and a small-molecule agonist (the latter serving as a second drug administered after surgery). According to this strategy, the injection is precisely delivered to the posterior substantia innominata brain region by means of stereotactic intracranial injection, and then the second drug is administered after surgery, so as to intervene in the social behavioral abnormalities associated with autism spectrum disorder. The therapy can prolong the attack latency, shorten the duration of aggressive behaviors, and reduce the frequency of aggressive episodes in model animals, while not interfering with basic vital activities and emotional states such as normal social interaction, fear and anxiety. This strategy pioneers a novel approach for treating autism spectrum disorder, which is expected to improve the quality of life of patients and alleviate the burdens on the families thereof and society, and thus has broad prospects for clinical application.

This invention relates to the field of biomedical information technology, and more particularly to a method for constructing an autism spectrum disorder (ASD) identification model based on deep learning. The method includes the following steps: acquiring videos of conversations with autistic patients; continuously monitoring the eye fixation frequency in the videos; when the eye fixation frequency is detected to be below a threshold, determining it as a reduced eye fixation state and recording the duration of eye fixation; performing sociolinguistic analysis on the conversation videos to obtain sociolinguistic data; and identifying facial reaction features of the autistic patients in the conversation videos based on the sociolinguistic data and recording facial muscle reaction data. This invention, through data processing and deep learning technologies, assesses communication and social interaction impairments in autistic patients and constructs an ASD identification model, thereby improving the efficiency and accuracy of ASD identification.

The invention belongs to the technical field of gene engineering, and particularly relates to an SNP site related to autism spectrum disorder of children and application of the SNP site. According to the SNP site related to the autism spectrum disorder of the children, the SNP site is located at the 69599651bp position on a 7g22 chromosome, and A / G base mutation exists. In an autism spectrum disorder patient case group, the mutation frequency of the site is obviously higher than that of a healthy control group, and the site and autism spectrum disorder diseases are relatively strong in relevance, so that the site is possibly related to the ASD onset risk, and an auxiliary basis is provided for early diagnosis and early screening of ASD.

A system and method for risk assessment of an individual for autism spectrum disorder (ASD) has been provided. The system is using a non-invasive method for risk assessment of the individual, especially children, for ASD through prediction of metabolic potential of the bacteria residing in gastrointestinal tract of the individual. The system is configured to calculate a score, evaluated from the gut bacterial community's taxonomic abundance profile, which is indicative of its metabolic potential for production of a particular neuroactive compound. A set of metabolic pathways harboured by the bacterial community residing in gut has been utilized to develop an ASD diagnosis scheme that, when applied with the conventional screening tests, help in early diagnosis of the ASD. Further, the present disclosure also provides bacterial community based therapeutic approaches that can potentially minimize the side effects through maintaining the healthy cohort of bacteria in gut.

Provided herein are methods for decreasing expression and / or activity of one or more pathways associated with neurotransmitter transport and / or synaptic transmission, comprising contacting a cell with an effective amount of a composition comprising entrectinib, or a pharmaceutically acceptable salt thereof. Further provided herein are methods for treating autism spectrum disorder associated with one or more mutations including the q12 band of chromosome 19 (19q12 ASD) in subjects in need thereof, by administering compositions comprising entrectinib to the subject.

This invention provides an AAV vector for treating autism spectrum disorder (ASD), and more particularly provides one capable of expressing human [specific autism spectrum disorder] in the brain. MEF2C AAV vector for gene expression. Specifically, this invention provides an adeno-associated virus vector capable of expressing the complete MEF2C protein and its applications. The adeno-associated virus vector of this invention can significantly improve… Mef2c Social deficit symptoms in mice with gene deletion.

The present invention relates to a method for treating autism spectrum disorder, a mouse for monitoring autism spectrum disorder, and a method for screening a candidate for preventing or treating autism spectrum disorder. Specifically, according to the present invention, the output signal (or excitation of population) of neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum may be suppressed by introducing a halorhodopsin protein into neurons of the ventrolateral thalamus (VL), the laterodorsal thalamus (LD) or the striatum and then irradiating light to induce hyperpolarization of the halorhodopsin protein. Thus, the present invention has the effect of preventing or treating autism.

Systems, methods and compositions are provided for the prophylaxis and / or treatment of autism spectrum disorder (ASD) (genetic, environmental and / or infection-induced) and other neuropsychological conditions by improving or correcting Aβ42 proteinopenia (low levels) and improving or restoring normal α7 nicotinic acetylcholine receptor signaling in patients. Therapeutic agents include Aβ polypeptide replacement therapy and neprilysin inhibitors.

Disease modification of specific neurodevelopmental disorders is demonstrated for preschool children through modulation of specific biogenic amine neurotransmitters and y-aminobutyric acid (GABA) / glutamine. In specific, cumulative reductions in maladaptive behaviors that interfere with activities of daily living for preschool populations are achieved through staged, long term, treatment. Additionally, a prophylaxis for certain neurodegenerative disorders is presented. Provided herein are compositions comprising digestive enzyme preparations and methods of using same for treating an Autism Spectrum Disorder (ASD).

The application discloses an intelligent teaching method fusing sound, meaning and object, and the method is characterized in that: initial course sets are matched by quantized scoring and ability grading matching through acquisition of evaluation questionnaire data, teaching path sequences are generated through a path planning algorithm, mapping is performed from five sensory perception dimensions and structured courseware sequences are assembled, real operation videos are received after the courseware is presented to a parent terminal, test result reports are generated through multi-modal three-level cascade evaluation, and it is judged whether to trigger path adjustment and update the ability vector to regenerate the adjusted path according to the test result report. The application solves the technical problems of single teaching dimension, weak generalization ability and lack of personalized adaptation in the prior art, and meets the strict quality requirements of family intervention for children with spectrum disorders.

The invention relates to the technical field of computer-aided diagnosis, in particular to a double-view autism detection method and system based on asynchronous brain function prior. The method comprises the following steps: firstly, acquiring an original fNIRS blood oxygen data sequence and double-view video data of a subject during an experimental task; constructing a global neural encoder by adopting a VGG-like depth one-dimensional convolution architecture, and extracting spatial-temporal features of brain functions to generate a global neural feature vector; constructing a cross-modal channel attention generation network, and generating a channel attention weight vector; injecting the channel attention weight vector into a self-attention module for video feature extraction, and performing channel-level dynamic calibration; and calculating a differential representation vector by adopting a double-flow feature alignment module of time delay perception, and outputting a prediction result of the autism spectrum disorder. According to the method, on the premise that strict time synchronization is not needed, random action noise irrelevant to pathology in the video can be dynamically inhibited, and behavior defect characteristics relevant to neural abnormality can be amplified.